We are live on
!
Find out more
Handelsbanken Fonder Portfolio holdings
AUM
$35.1B
1-Year Est. Return
47.76%
This Fund
S&P 500
This Quarter
Est. Return
+2.36%
1 Year Est. Return
+47.76%
3 Year Est. Return
+137.96%
5 Year Est. Return
+170.36%
10 Year Est. Return
+934.7%
AUM
$26.2B
AUM Growth
+$914M
(+3.6%)
Cap. Flow
+$1.01B
Cap. Flow
% of AUM
3.87%
Top 10 Holdings %
Top 10 Hldgs %
32.55%
Holding
1,591
New
69
Increased
817
Reduced
431
Closed
49
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$107M |
| 2 |
EXL Service
EXLS
|
+$72M |
| 3 |
Apple
AAPL
|
+$64.3M |
| 4 |
Synopsys
SNPS
|
+$56.8M |
| 5 |
ServiceNow
NOW
|
+$54.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Halozyme
HALO
|
+$74.5M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$53.5M |
| 3 |
Edwards Lifesciences
EW
|
+$45M |
| 4 |
Abbott
ABT
|
+$40.3M |
| 5 |
Rockwell Automation
ROK
|
+$39.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 37.4% |
| 2 | Healthcare | 16.63% |
| 3 | Financials | 12.04% |
| 4 | Communication Services | 9.47% |
| 5 | Industrials | 8.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1026
Guardant Health
GH
$21.4B
| $884K | ﹤0.01% |
28,941
+1,800
| +7% | +$50.6K |
|
|
NARI
1027
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $883K | ﹤0.01% |
17,300
+1,300
| +8% | +$63.9K |
|
1028
Hecla Mining
HL
$11.9B
| $878K | ﹤0.01% |
178,816
+27,000
| +18% | +$161K |
|
1029
Four Corners Property Trust
FCPT
$2.76B
| $876K | ﹤0.01% |
32,295
+3,600
| +13% | +$103K |
|
1030
Madison Square Garden
MSGS
$9.94B
| $874K | ﹤0.01% |
3,872
+400
| +12% | +$89.3K |
|
1031
Travel + Leisure Co
TNL
$4.58B
| $873K | ﹤0.01% |
17,300
+500
| +3% | +$25.4K |
|
1032
Blackbaud
BLKB
$2.1B
| $867K | ﹤0.01% |
11,730
+900
| +8% | +$73.6K |
|
1033
Cogent Communications
CCOI
$530M
| $865K | ﹤0.01% |
11,230
| – | – |
|
1034
RXO
RXO
$3.85B
| $865K | ﹤0.01% |
36,300
+14,300
| +65% | +$399K |
|
1035
Neogen
NEOG
$2.59B
| $858K | ﹤0.01% |
70,664
+6,400
| +10% | +$89.5K |
|
1036
Twist Bioscience
TWST
$7.86B
| $855K | ﹤0.01% |
+18,400
| New | +$832K |
|
1037
Avient
AVNT
$4.23B
| $853K | ﹤0.01% |
20,881
| – | – |
|
1038
Urban Edge Properties
UE
$2.78B
| $853K | ﹤0.01% |
39,690
+3,900
| +11% | +$86.8K |
|
1039
StepStone Group
STEP
$4.28B
| $852K | ﹤0.01% |
14,728
| – | – |
|
1040
Uranium Energy
UEC
$5.54B
| $850K | ﹤0.01% |
127,100
+5,900
| +5% | +$45.2K |
|
1041
ICU Medical
ICUI
$4.58B
| $849K | ﹤0.01% |
5,472
-1,300
| -19% | -$220K |
|
|
NUVL
1042
DELISTED
Nuvalent
NUVL
| $845K | ﹤0.01% |
10,800
+1,500
| +16% | +$140K |
|
|
SWTX
1043
DELISTED
SpringWorks Therapeutics
SWTX
| $845K | ﹤0.01% |
23,400
| – | – |
|
1044
Acadia Healthcare
ACHC
$2.82B
| $844K | ﹤0.01% |
21,274
-600
| -3% | -$27.1K |
|
1045
Timken Company
TKR
$9.1B
| $842K | ﹤0.01% |
11,800
-300
| -2% | -$23.6K |
|
1046
Li Auto
LI
$12B
| $840K | ﹤0.01% |
35,000
-35,000
| -50% | -$868K |
|
1047
Credit Acceptance
CACC
$6.05B
| $838K | ﹤0.01% |
1,786
| – | – |
|
1048
First Hawaiian
FHB
$3.39B
| $838K | ﹤0.01% |
32,309
| – | – |
|
|
PPLI
1049
People Inc
PPLI
$3.01B
| $837K | ﹤0.01% |
23,649
+3,048
| +15% | +$122K |
|
|
UCB
1050
United Community Banks
UCB
$4.43B
| $835K | ﹤0.01% |
25,839
+2,700
| +12% | +$84K |
|
Similar funds
GAM
Handelsbanken Fonder's Q4 2024 Portfolio in Review
As of Q4 2024, Handelsbanken Fonder held 1,591 positions worth $26.2B, up 3.6% from $25.3B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Handelsbanken Fonder deployed $1.01B of net new capital in Q4 2024, opening 69 new positions and adding to 817 existing holdings. Its largest new stake was GE Vernova: 105,537 shares worth $34.7M.
By sector, the portfolio is most concentrated in Technology at 37% of assets, up from 35% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Halozyme, an estimated $74.5M trimmed.
- Handelsbanken Fonder's largest Q4 2024 buy was GE Vernova: 105,537 shares worth $34.7M.
- Handelsbanken Fonder added most to Microsoft in Q4 2024, an estimated $107M increase.
- Handelsbanken Fonder's biggest Q4 2024 reduction was Halozyme, cutting an estimated $74.5M.
- Handelsbanken Fonder fully exited BeOne Medicines Ltd in Q4 2024, selling an estimated $5.92M.
- Handelsbanken Fonder's ten largest holdings make up 33% of its $26.2B portfolio in Q4 2024.
- Handelsbanken Fonder opened 69 new positions and closed 49 in Q4 2024.
- Handelsbanken Fonder's portfolio value rose 3.6% quarter-over-quarter to $26.2B.
Based on Handelsbanken Fonder's 13F filing for Q4 2024, filed 3 Feb 2025.